Perspective Therapeutics, Inc.
CATX
$3.90
-$0.03-0.76%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.20% | -30.96% | -15.64% | -3.60% | 1.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.20% | -30.96% | -15.64% | -3.60% | 1.39% |
| Cost of Revenue | 101.37% | 82.86% | 95.41% | 100.14% | 149.17% |
| Gross Profit | -106.49% | -88.22% | -101.51% | -107.25% | -163.14% |
| SG&A Expenses | 13.60% | 35.27% | 47.90% | 40.92% | 26.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.69% | 61.78% | 72.65% | 68.58% | 61.06% |
| Operating Income | -70.01% | -64.28% | -75.30% | -71.07% | -63.15% |
| Income Before Tax | -29.84% | -117.68% | -120.46% | -104.06% | -100.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.31% | -84.40% | -83.23% | -68.10% | -109.13% |
| Earnings from Discontinued Operations | 154.16% | 108.38% | 107.43% | 93.91% | 89.52% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.07% | -65.87% | -60.89% | -45.79% | -70.46% |
| EBIT | -70.01% | -64.28% | -75.30% | -71.07% | -63.15% |
| EBITDA | -71.04% | -64.42% | -74.67% | -69.38% | -61.41% |
| EPS Basic | -12.40% | 1.54% | 18.78% | 34.28% | 25.29% |
| Normalized Basic EPS | -59.92% | -11.79% | 12.06% | 32.89% | 41.35% |
| EPS Diluted | -12.40% | 1.54% | 18.78% | 34.28% | 25.29% |
| Normalized Diluted EPS | -59.92% | -11.79% | 12.06% | 32.89% | 41.35% |
| Average Basic Shares Outstanding | 17.52% | 32.78% | 63.46% | 105.06% | 134.78% |
| Average Diluted Shares Outstanding | 17.52% | 32.78% | 63.46% | 105.06% | 134.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |